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The p53 pathway has an important role in cell cycle arrest and apoptosis. Downregulated levels of p53 have been shown to in-
crease resistance to the cytotoxic effects of chemotherapy or radiotherapy. MDM2 (murine double minute 2) is able to bind p53 
and modulate its transcriptional activity and stability. We studied the effect of Nutlin-3a, an MDM2 antagonist, on the response of 
non-small cell lung cancer cell lines, A549 (p53+/+) and H1299 (p53/), to paclitaxel (Taxol). A549 cells treated with Nutlin-3a 
plus paclitaxel showed a significant increase in MDM2 and wild-type p53 protein, a marked increase in the number of cells in the 
G0-G1 and G2-M phases, and a significant decrease in the percentage of cells in the S phase. The percentage of apoptotic A549 
cells treated with 10 mol/L Nutlin-3a plus 10 nmol/L paclitaxel was significantly lower than those treated with paclitaxel alone, 
and was also lower than that observed in H1299 cells. MTT assays demonstrated that Nutlin-3a plus paclitaxel also significantly 
reduced the sensitivity of A549 cells to paclitaxel compared with that of H1299 cells. In conclusion, Nutlin-3a mediates the cyto-
toxic effect of paclitaxel depending on p53 status. It may also protect wild-type p53 cells from mitotic chemotherapeutics. 
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Lung cancer is the leading cause of cancer-related deaths in 
the world with the number of deaths more than 1180000 
annually [1]. Because 65% of lung cancer patients are in the 
advanced stage, and about 80% of lung cancer is composed 
of non-small cell carcinomas (NSCLC), chemotherapy is 
the main treatment. However, NSCLC is more resistant to 
chemotherapy than other forms of cancer [2,3]. Therefore, 
the development of a novel and efficient therapy to sensitize 
NSCLC to chemotherapy is urgently required. 
The p53 pathway has an important role in cell cycle ar-
rest and apoptosis. Defects in the p53 network are thought 
to be involved in a massive percentage of tumors [4,5]. 
Restoration of the p53 tumor suppressor pathway should, in 
theory, trigger considerable apoptosis of the tumor. In addi-
tion, downregulated levels of p53 have been shown to in-
crease resistance to the cytotoxic effects of chemotherapy or 
radiotherapy [6,7]. Hence, p53 is an appealing target for 
novel anticancer therapeutic strategies. 
Murine double minute 2 (MDM2) is the primary negative 
regulator of p53, and is an E3 ubiquitin ligase that trans-
ports p53 to the cytoplasm, where it promotes p53 ubiquiti-
nation and degradation by the proteasome [8]. In proliferat-
ing cells, p53 levels are tightly controlled by MDM2, which 
modulates its transcriptional activity and stability following 
binding [9–11]. MDM2 and p53 form a negative feedback 
loop [12]; therefore, it is possible to activate the p53 path-
way by inhibiting MDM2. 
Recently, small-molecule inhibitors of MDM2, Nutlins, 
have been developed, and found to have a high affinity for 
MDM2, preventing binding to p53 [13–15]. Nutlins can 
release p53 from the negative control of MDM2 and acti-
vate the p53 pathway to promote cell cycle arrest and apop-
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tosis in cancer cells that express wild-type p53. Nutlin-3a 
increases radiosensitivity of H460 and Val138 cells [16], 
and sensitizes cancer cells to chemotherapeutic agents such 
as cisplatin, and etoposide [17]. However, some researchers 
found that Nutlins can protect non-malignant cells and tis-
sues [18,19]. Therefore, it is not clear whether Nutlins are 
effective agents for chemosensitization, or are able to pro-
tect cells from chemotherapy in wild-type p53 and p53- 
deficient cancer cells. 
The objective of this study was to evaluate the effects of 
Nutlins on NSCLC cell lines, A549 (wild-type p53) and 
H1299 (p53-deficient), when used in conjunction with a 
commonly used chemotherapeutic, paclitaxel. 
1  Materials and methods 
1.1  Cell culture  
Human NSCLC cell lines A549 and H1299 were cultured in 
RPMI-1640 with 10% fetal calf serum (FBS, Gibco, Grand 
Island, NY, USA) and Dulbecco Modified Eagle Medium 
supplemented with 10% FBS at 37°C in 5% CO2, respec-
tively. Cells were used when in the exponential growth 
phase. 
1.2  Reagents  
Nutlin-3a (Sigma-Aldrich, St. Louis, MO, USA) was dis-
solved in DMSO and stored as 20 mg/mL stock solution in 
small aliquots at 20°C to avoid repeated freeze-thaw cy-
cles. A stock solution of 1×106 nmol/L paclitaxel (Hainan 
Shunyuan Chemotech, Hainan, China) diluted in alcohol 
was stored at 20°C. Anti-MDM2 (SMP14) and anti-p53 
(DO-1) antibodies were purchased from Santa Cruz Biotech-
nology Inc. (Santa Cruz, CA, USA). Anti--actin (AC-15) 
antibody was from Sigma-Aldrich. All other reagents were 
from Sigma-Aldrich unless otherwise stated. 
1.3  Western blot analysis 
A549 and H1299 cells were incubated with 10 mol/L Nut-
lin-3a, 10 nmol/L paclitaxel and a combination of 10 mol/L 
Nutlin-3a + 10 nmol/L paclitaxel in 25 cm
2 flasks in 5 mL 
medium for 8 h. Cells were harvested and lysed in protein 
lysis buffer. Equal amounts of protein lysate were loaded 
into each well and separated by 10% sodium dodecylsulfate- 
polyacrylamide gel electrophoresis for 2 h at 100 V, fol-
lowed by transferring proteins to a nitrocellulose membrane 
(Amersham Biosciences, Piscataway, NJ, USA). Mem-
branes were incubated with primary antibodies against p53 
(1:500; Santa Cruz Biotechnology), MDM2 (1:500; Santa 
Cruz Biotechnology), and -actin (Sigma-Aldrich) over-
night at 4°C, followed by secondary horseradish peroxidase- 
conjugated goat anti-mouse antibody (1:2000; Sigma-  
Aldrich). -actin was used for loading control in all experi-
ments. Proteins were traced by enhanced chemilumines-
cence Western blot detection reagent (Amersham Biosci-
ences). Optical density (OD) protein levels were normalized 
to corresponding -actin and results were expressed as an 
OD ratio. 
1.4  Cell cycle analysis 
A549 and H1299 cells were treated with a DMSO vehicle 
(untreated control), 5 mol/L Nutlin-3a, 10 nmol/L paclitaxel 
or a combination of 5 mol/L Nutlin-3a and 10 nmol/L 
paclitaxel for 48 h. After treatment, cells were collected 
with 0.25% Trypsin (Gibco) and washed twice in 0.01 
mol/L PBS. After centrifugation at 2000 r/min for 5 min, 
cells were suspended in PBS and fixed in ice-cold ethanol 
(70%, v/v) at 4°C overnight and stained with 1 mL propidium 
iodide (PI) solution (50 g/mL PI, 100 g/mL RNAase A, 10 
mmol/L EDTA, 0.5% Triton X-100) at 4°C for 30 min in 
the dark. Cell cycle distribution of samples was determined 
using a FACScan flow cytometer (Becton, Dickinson and 
Company, Franklin Lakes, NJ, USA), and data were ana-
lyzed using ModFit and CellQuEST software (Becton, 
Dickinson and Company). 
1.5  Cell apoptosis analysis 
A549 and H1299 cells were treated with a DMSO vehicle 
(untreated control), 5 mol/L Nutlin-3a, 10 nmol/L paclitaxel 
or a combination of 5 μmol/L Nutlin-3a and 10 nmol/L 
paclitaxel for 48 h. After treatment, cells were collected 
with 0.25% Trypsin and washed twice in chilled 0.01 mol/L 
PBS. After centrifugation at 2000 r/min for 5 min, cells 
were suspended in Flow Cytometry Buffer and adjusted to a 
concentration of 1×106 cells/mL. Next, 5 L AnnexinV/ 
FITC and 10 L PI solution were added to 100 L cell sus-
pension for 15 min in the dark. Samples were measured 
using a FACScan flow cytometer (Becton, Dickinson and 
Company). Cell apoptosis was analyzed using WinMDI2.9 
software (Becton, Dickinson and Company). 
1.6  MTT assays 
The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium-     
bromide (MTT, Sigma-Aldrich) assays were used to survey 
and evaluate cell survival in a quantitative colorimetric assay. 
The cells (3×103/well) were seeded into 96-well plates and 
incubated at 37°C in RPMI-1640 and DMEM mediums 
respectively. After 24 h culture, A549 and H1299 cells were 
treated with varying concentrations of paclitaxel (0, 0.1, 1, 
10, 100, 1000 nmol/L) and Nutlin-3a (0, 5, 10, 15 mol/L) 
for 72 h, and 10 nmol/L paclitaxel and/or 5 mol/L Nutlin- 
3a for variable time points (0, 24, 48, 72 h) in quintuplet. 
Medium alone, and medium plus DMSO acted as control 
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for each dilution. A 20 L volume of MTT was added to 
each well, then plates were incubated for an additional 4 h 
at 37°C. The medium was then removed and replaced with 
150 L DMSO in each well. Plates were shaken for 15 min 
at room temperature, and read at 490 nm in a Bio-Rad 680 
Microplate reader (Bio-Rad Laboratories, Inc., Berkeley, 
CA, USA). 
1.7  Statistical analysis 
Data were expressed as means ± standard deviations (SD). 
Statistical significance between groups was determined by 
the analysis of variance and Student-Newman-Keuls multiple 
comparison test (q test) after confirming the equality of 
variance with the Levene test using SPSS statistical soft-
ware version 13.0 (SPSS Inc., Chicago, IL, USA). P < 0.05 
was deemed statistically significant. 
2  Results  
2.1  Expression of p53 and MDM2 protein 
Expression of wild-type p53 and MDM2 protein was deter-
mined by Western blot. As shown in Figure 1, wild-type 
p53 is expressed in A549 cells but not in H1299 cells, while 
MDM2 is expressed in both A549 and H1299 cell lines. The 
addition of Nutlin-3a to A549 cells resulted in dose-dependent 
increases in p53 and MDM2 protein expressions. In contrast, 
there was no change in MDM2 and p53 expressions in 
H1299 cells. A549 cells treated with Nutlin-3a or paclitaxel 
demonstrated a slight increase in wild-type p53 and MDM2 
protein, but those treated with Nutlin-3a plus paclitaxel 
showed significant upregulation. Conversely, there was al-
most no increase in wild-type p53 and MDM2 protein in 
H1299 cells treated with Nutlin-3a and/or paclitaxel. 
2.2  Cell cycle arrest by Nutlin-3a and paclitaxel 
To determine if Nutlin-3a inhibition of MDM2 affects pro-
gression through the cell cycle, A549 and H1299 cells were 
treated with a vehicle or Nutlin-3a followed by paclitaxel. 
The percentage of cells in each stage of the cell cycle was 
then determined using flow cytometry. As shown in Figure 
1(a), A549 cells treated with Nutlin-3a alone showed a de-
crease in the proportion in the S phase (11.4% vs. 27% con-
trol), a greater increase in the percentage of cells in G0-G1 
(72.1% vs. 59% control), and a slight increase in the per-
centage of cells in G2-M (16.5% vs. 14% control). A549 
cells treated with Nutlin-3a plus paclitaxel showed a marked 
increase in the number of cells in G0-G1 (71.7%) and G2-M 
phase (20.9%), and a significant decrease in the percentage 
of cells in the S phase (7.4%). In contrast, there was almost 
no change in cell cycle distribution following administration 
of Nutlin-3a and/or paclitaxel (Figure 2(a)). 
2.3  Nutlin-3a protects wild-type p53 cells from 
paclitaxel-induced apoptosis 
The percentage of apoptotic A549 cells treated with 10 mol/L 
Nutlin-3a plus 10 nmol/L paclitaxel was 13.7% ± 1.67%, 
which was significantly lower compared with that in H1299 
cells (34.8% ± 3.52%, P < 0.05) (Figure 2(b)). 
 
Figure 1  (a) Expression of MDM2 and wild-type p53 in A549 and H1299 cells or (b) in A549 and H1299 cells treated with varying concentrations of 
Nutlin-3a (0, 5, 10, 30 mol/L). (c) A549 and (d) H1299 cells were incubated in 25-cm2 flasks in 5-mL medium for 8 h with vehicle (untreated control),   
10 mol/L Nutlin-3a, 10 nmol/L paclitaxel, or a combination of 10 mol/L Nutlin-3a and 10 nmol/L paclitaxel. Expressions of MDM2 and wild-type p53 
protein were determined using Western blot. PTX, paclitaxel; Nut, Nutlin-3a. 
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Figure 2  Cell cycle distribution and apoptosis. (a) Effect of Nutlin-3a 
and paclitaxel (PTX) on cell cycle arrest. Cell cycle distribution following 
24 h treatment with DMSO (control), 5 mol/L Nutlin-3a, 10 nmol/L PTX 
or a combination of 5 mol/L Nutlin-3a pre-treatment for 24 h and then 10 
nmol/L PTX. (b) Apoptosis induced by 5 mol/L Nutlin-3a, 10 nmol/L 
PTX or a combination of 5 mol/L Nutlin-3a and 10 nmol/L PTX for 48 h. 
Percentage of apoptotic cells was determined by flow cytometry. * P < 0.05.  
2.4  Nutlin-3a reduces sensitivity of wild-type p53 cells 
to paclitaxel 
A549 and H1299 cell lines were exposed to increasing doses  
of paclitaxel alone or in combination with 5, 10 or 20 mol/L 
Nutlin-3a for 72 h. Nutlin-3a plus paclitaxel significantly 
reduced the sensitivity of A549 cells compared with that in 
H1299 cells (P < 0.05) (Figure 3). In another experiment, 
A549 and H1299 cells were pretreated with 10 mol/L Nut-
lin-3a for 24 h, and/or treated with 10 nmol/L paclitaxel for 
an additional 24, 48 or 72 h. Nutlin-3a protected A549 cells 
from paclitaxel (Figure 3). 
3  Discussion 
Chemotherapy is the main treatment modality for most 
NSCLC patients, but there are many side-effects, such as 
hematologic toxicity, gastrointestinal reaction, second ma-
lignancies and drug hypersensitivity. Hence, there is an ur-
gent need to reduce the dosage of chemotherapeutic agents 
and to sensitize cancer cells to chemotherapy. However, 
caution must be exercised when choosing the right agents to 
sensitize cells to chemotherapy. 
The p53 tumor suppressor gene controls the activity of 
multiple genes involved in cell aging, cell cycle arrest, and 
apoptosis [20]. The p53 has an important role in preventing  
 
Figure 3  Cell survival percentage was determined using MTT assays. (a), (c) A549 and H1299 cell lines were exposed to increasing doses of paclitaxel 
(PTX) alone or in combination with 5, 10 and 20 mol/L Nutlin-3a for 72 h. Nutlin-3a significantly protects A549 cells from PTX in comparison with 
H1299 cells (P < 0.05). (b), (d) A549 and H1299 cell lines were pre-treated with 10 mol/L Nutlin-3a for 24 h, and/or treated with 10 nmol/L PTX for an 
additional 24, 48 or 72 h. 
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tumor formation through transcription-dependent and tran-
scription-independent pro-apoptotic activities. One major 
function of p53 is the activation of G1-S and G2-M check-
points of the cell cycle through transcriptional stimulation 
of p21 [21]. The p53 also can trigger mitochondrial outer 
membrane permeabilization and apoptosis in the absence of 
transcription through direct activation of Bax or Bak or 
through binding to Bcl-2 or Bcl-XL. The expression of wild- 
type p53 in most NSCLC represents a potent molecular tar-
get for therapy [22]. 
As a main regulator of tumorigenesis and progression, 
MDM2 inhibits the expression of wide-type p53, suggesting 
that the inhibition of MDM2 partially contributes to the 
elevated activity of wild-type p53 in NSCLC [23,24]. MDM2 
and p53 form a negative feedback loop [12], which is very 
important for tumorigenesis. If the feedback loop is inter-
rupted by an agent such as Nutlin-3a, the tumor cell will 
undergo apoptosis. Nutlin-3a has been studied as an effec-
tive agent to induce cell cycle arrest and apoptosis in some 
tumors, and has been found to increase radiosensitivity of 
H460 and Val138 cells [16], and to sensitize cells to chemo-
therapeutic agents such as cisplatin and etoposide [17]. To 
date, there has been no study of Nutlin-3a as a chemosensi-
tizer for the commonly used agent paclitaxel. 
In our study, we detected the expression of MDM2 and 
wild-type p53 in A549 and H1299 cells treated with paclitaxel 
or paclitaxel plus Nutlin-3a using Western blot. We found 
that A549 cells treated with Nutlin-3a plus paclitaxel 
showed a significant upregulation of MDM2 and wild-type 
p53 proteins, but this effect was not observed in H1299 
cells undergoing the same treatment regime. These results 
showed that Nutlin-3a effectively inhibited the activity of 
MDM2 and enhanced the wild-type p53 activity, and that 
there was a synergistic effect of Nutlin-3a and paclitaxel in 
wild-type p53 cells. 
Paclitaxel is a cell cycle-dependent chemotherapeutic 
that targets mitotic cells. A549 cells treated with Nutlin-3a 
alone showed a greater increase in the percentage of cells in 
G0-G1 phase. A549 cells treated with Nutlin-3a plus paclitaxel 
showed a marked increase in the number of cells in G0-G1 
and G2-M phase, and a significant decrease in the percent-
age of cells in the S phase. Nutlin-3a could arrest cell cycle 
at the G0-G1 and G2-M phases in these cells. Nutlin-3a plus 
paclitaxel protected wild-type p53 cells from the cytotoxic 
effects of paclitaxel. However, Nutlin-3a had no effect on 
the cell cycle of p53-deficient (H1299) cells, suggesting it 
has no protecting effect. The percentage of apoptotic A549 
cells treated with 5 mol/L Nutlin-3a plus 10 nmol/L paclitaxel 
was significantly lower than those only treated with paclitaxel, 
and compared with the effect observed in H1299 cells. Pro-
liferation assay results showed that Nutlin-3a plus paclitaxel 
also significantly reduced A549 cell sensitivity to paclitaxel 
compared with H1299 cells. Considering all this evidence, 
Nutlin-3a appears to interrupt the MDM2-p53 feedback 
loop. The elevation of p53 affected the expression of down-
stream genes such as p21, Bcl-2, Bax, causing cell cycle 
arrest in the G0-G1 and G2-M phases, which results in re-
sistance to mitotic chemotherapeutics such as paclitaxel. 
Therefore, the combination of Nutlin-3a and mitotic chemo-
therapeutics is not a wise choice for treatment of cancers 
expressing wild-type p53.  
In conclusion, Nutlin-3a mediates the cytotoxic effect of 
paclitaxel depending on the p53 status. It may protect wild- 
type p53 cells from mitotic chemotherapeutics, and there-
fore it is necessary to choose combined chemotherapeutic 
agents with caution and to develop treatments individually.  
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